Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease
- Gut, Sep 06 2024, gutjnl-2024-332687 | https://doi.org/10.1136/gutjnl-2024-332687